Related Experiment Video

Updated: Aug 31, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

In vitro metabolism of perospirone in rat, monkey and human liver microsomes

Yoshiko Mizuno1, Naoko Tani, Setsuko Komuro

  • 1Environmental Health Science Laboratory, Sumitomo Chemical Co., Ltd. Kasugade-Naka, Konohana-Ku, Osaka, Japan.

European Journal of Drug Metabolism and Pharmacokinetics
|September 25, 2003
PubMed

Insights

This study investigated the in vitro metabolism of perospirone across different species and liver preparations. Key findings reveal distinct metabolic pathways, primarily involving oxidation and cleavage, with limited genetic polymorphism concerns for clinical use.

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Biochemistry
  • Medicinal Chemistry

Background:

  • Understanding the metabolic fate of perospirone is crucial for its therapeutic application.
  • In vitro studies provide essential insights into drug biotransformation pathways.
  • Species-specific metabolic differences can impact drug efficacy and safety.

Purpose of the Study:

  • To elucidate the in vitro metabolic pathways of perospirone in rat, monkey, and human liver systems.
  • To identify major perospirone metabolites and the enzymes involved in their formation.
  • To assess the potential for drug-drug interactions and genetic polymorphism related to perospirone metabolism.

Main Methods:

  • Incubation of 14C-labeled perospirone with rat, monkey, and human liver S9 fractions.
  • Incubation with human liver microsomes and yeast microsomes expressing specific human cytochrome P450 (CYP) enzymes.
  • Identification and quantification of metabolites using analytical techniques.

Main Results:

  • Major metabolic pathways identified include oxidation of the cyclohexane ring, oxidative cleavage of the butylene side chain, and S-oxidation.
  • Species differences were observed in the proportions of metabolites formed, with distinct major metabolites in rat, monkey, and human systems.
  • Cytochrome P450 3A4 (CYP3A4) was identified as a significant contributor to perospirone metabolism in humans, suggesting low risk of genetic polymorphism issues.

Conclusions:

  • The primary metabolic pathways for perospirone in humans involve oxidation and cleavage, consistent across liver S9 and microsomes.
  • Significant interspecies variations in metabolite profiles were noted, highlighting the importance of human-specific data.
  • The substantial role of CYP3A4 suggests that genetic variations in this enzyme are unlikely to cause significant clinical problems for perospirone.

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Related Concept Videos

Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...